Looking for breakthrough ideas for innovation challenges? Try Patsnap Eureka!

Application of fidaxomicin in preparation of product for inhibiting activity of mycobacterium avium

A technology of Mycobacterium avium and Fidaxomycin, applied in the field of medicine, can solve the problems that Fidaxomycin has not yet been reported to inhibit Mycobacterium avium

Inactive Publication Date: 2021-01-08
BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV +3
View PDF6 Cites 0 Cited by
  • Summary
  • Abstract
  • Description
  • Claims
  • Application Information

AI Technical Summary

Problems solved by technology

[0005] There is no report on the inhibition of Mycobacterium avium by fidaxomicin

Method used

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
View more

Image

Smart Image Click on the blue labels to locate them in the text.
Viewing Examples
Smart Image
  • Application of fidaxomicin in preparation of product for inhibiting activity of mycobacterium avium
  • Application of fidaxomicin in preparation of product for inhibiting activity of mycobacterium avium
  • Application of fidaxomicin in preparation of product for inhibiting activity of mycobacterium avium

Examples

Experimental program
Comparison scheme
Effect test

Embodiment 1

[0044] Embodiment 1, Fidaxomycin is detected to the antibacterial activity of Mycobacterium avium standard strain

[0045] Drug to be tested: Fidaxomicin

[0046] 1. Add 100 μl of Mueller Hinton (MH) medium (containing 5% OADC) to each well of a 96-well plate;

[0047] 2. After completing step 1, take the 96-well plate and add 100 μl of the drug solution to be tested (prepared in DMSO) with a concentration of 128 μg / mL in the 12th column. After the second column, take out 100 μl and discard it, and the first column does not contain drug, which is the positive control well. Three replicate wells were set up for each concentration.

[0048] 3. After completing step 2, take the 96-well plate and add 100 μl of the bacterial suspension of Mycobacterium avium standard strain ATCC 25291 to each well, so that the final volume in each well is 200 μl, and the final concentration of the bacterial solution is 2.5×10 5 CFU / mL; see Table 1 for the final drug concentration in each column ...

Embodiment 2

[0060] Embodiment 2, Fidaxomycin is detected to the bacteriostatic activity of clinical isolate Mycobacterium avium bacterial strain

[0061] Clinically isolated strains: 35 strains were isolated and cultured from sputum specimens of patients infected with Mycobacterium avium, and were identified as Mycobacterium avium by sequencing of 16SrRNA, hsp65, rpoB, and 16-23S rRNA regions.

[0062] Drug to be tested: Fidaxomicin.

[0063] According to the method in Example 1, the bacteriostatic activity of the drug to be tested to 35 clinically isolated Mycobacterium avium strains was detected.

[0064] The MIC results are shown in Table 2. The statistical results of MIC concentration distribution are shown in Table 3 and figure 1 shown.

[0065] Table 2 Bacteriostatic activity of fidaxomicin to clinical isolates of Mycobacterium avium strains

[0066]

[0067]

[0068] Table 3 Statistical results of the MIC concentration distribution of fidaxomicin to clinical isolates of M...

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

PUM

No PUM Login to View More

Abstract

The invention discloses application of fidaxomicin in preparation of a product for inhibiting the activity of mycobacterium avium. The invention provides application of fidaxomicin or pharmaceuticallyacceptable salt thereof or a substance taking fidaxomicin or pharmaceutically acceptable salt thereof as an active ingredient in preparation of a product for inhibiting the activity of mycobacteriumavium. According to the application of the fidaxomicin, the fidaxomicin anti-mycobacterium avium activity determination is carried out by adopting a microwell plate double dilution method, the resultshows that the fidaxomicin has good antibacterial activity on mycobacterium avium standard strains and clinically separated mycobacterium avium, and the new application of the fidaxomicin in prevention and treatment of mycobacterium avium infection diseases is expected to be explored.

Description

technical field [0001] The invention relates to the technical field of medicine, in particular to the application of fidaxomicin in the preparation of products for inhibiting the activity of Mycobacterium avium. Background technique [0002] Non-tuberculous Mycobacteria (NTM) refers to mycobacteria other than Mycobacterium tuberculosis complex and Mycobacterium leprae. The characteristics of non-tuberculous mycobacteria are different from mycobacterium tuberculosis, such as being sensitive to acid and alkali; they are highly resistant to commonly used anti-tuberculosis drugs, such as isoniazid, rifampicin, streptomycin There are varying degrees of resistance to commonly used anti-tuberculosis drugs such as serotonin; the growth temperature is not as strict as that of Mycobacterium tuberculosis; it mostly exists in the environment; it is an opportunistic pathogen. In recent years, the infection caused by NTM has been on the rise gradually, posing a serious threat to human he...

Claims

the structure of the environmentally friendly knitted fabric provided by the present invention; figure 2 Flow chart of the yarn wrapping machine for environmentally friendly knitted fabrics and storage devices; image 3 Is the parameter map of the yarn covering machine
Login to View More

Application Information

Patent Timeline
no application Login to View More
Patent Type & Authority Applications(China)
IPC IPC(8): A61K31/7048A61P31/04
CPCA61K31/7048A61P31/04
Inventor 王桂荣黄海荣李浩
Owner BEIJING CHEST HOSPITAL CAPITAL MEDICAL UNIV
Who we serve
  • R&D Engineer
  • R&D Manager
  • IP Professional
Why Patsnap Eureka
  • Industry Leading Data Capabilities
  • Powerful AI technology
  • Patent DNA Extraction
Social media
Patsnap Eureka Blog
Learn More
PatSnap group products

Browse by: Latest US Patents, China's latest patents, Technical Efficacy Thesaurus, Application Domain, Technology Topic, Popular Technical Reports.

© 2024 PatSnap. All rights reserved.Legal|Privacy policy|Modern Slavery Act Transparency Statement|Sitemap|About US| Contact US: help@patsnap.com